Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinohio Research Services LLC

Neither a doctor nor a teaching hospital

Research payments

$177,454

98 payments

Through program year 2025, Clinohio Research Services LLC is reported as receiving $177,454 in research payments, across 98 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $20,961 13
2024 Research $31,343 7
2023 Research $13,937 8
2022 Research $40,243 21
2021 Research $13,068 13
2020 Research $41,546 27
2019 Research $16,357 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $48,688 46 payments
  2. AbbVie, Inc. $47,516 17 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $40,828 22 payments
  4. Evofem Biosciences, Inc. $40,422 13 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO $41,036 41 payments
  2. Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) $40,422 13 payments
  3. A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $37,409 12 payments
  4. BAY86-5028 Mirena extension contraception $18,402 10 payments
  5. BAY1454032 Essure System for Permanent Birth Control $17,353 9 payments
  6. A Phase 1/2, Randomized, Observer-Blinded, Multi-Country Study to Eval $7,651 5 payments
  7. M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $5,700 3 payments
  8. BAY1454032, Essure System for Permanent Birth Control $4,539 2 payments
  9. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy $2,948 1 payment
  10. A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $1,460 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Professional salary support $36,579 12 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record